This is what I liked at Roth presentation. Dr. M pointed out how he left blank the milestone payments from partnerships for 2013, but hinted they maybe near 18M this year. Making 2013 a breakeven year. Those 1B in partnership milestones are going to start wondering in. Specially watch Lee011 and AZD 5363 and AZD 3293. I noticed at ACCR one of our partners, listed the trial as presenting, but was very secret about what they will discuss. I will look up the presentation.
The presentation I mentioned above is on AZD5363. What's missing in the presentation is the body of the abstract. All it mentions is that they will release data on two ph1 on results and clinical evaluation on Japanese solid tumor trial with this drug.
Astra Zeneca will also be presenting clinical on CCT129254, this is a astex drug. They basically are looking at combination, this drug may benefit other drugs, where the cancer finds a pathway that CCT129254 inhibits.